# Carcinoma, Non-Small-Cell Lung trials: 987 new

Updated November 9, 2026.

987 clinical studies in Carcinoma, Non-Small-Cell Lung were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 362 have an industry sponsor and 831 are recruiting or about to. The newest, NCT07926308, was posted on November 9, 2026: Real-world Outcome of Zongertinib in Japan (J-HERZ) (Boehringer Ingelheim).

## The full list

New Carcinoma, Non-Small-Cell Lung clinical trials: 987 rows for $49.35, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 43 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/carcinoma-non-small-cell-lung

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 987
- Industry sponsored: 362
- Recruiting or not yet: 831
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 987, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926308 | Real-world Outcome of Zongertinib in Japan (J-HERZ) | Boehringer Ingelheim | Observational | Not yet recruiting | Non-small Cell Lung Cancer | 300 | Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926308) |
| November 6, 2026 | NCT07922135 | Moderately Hypofractionated Versus Conventional Chemoradiotherapy With Consolidation Immunotherapy in Patients With Unresectable... | Trans Tasman Radiation Oncology Group | Not applicable | Not yet recruiting | Stage III NSCLC | 300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922135) |
| November 6, 2026 | NCT07921888 | Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA | Eun Hye Lee | Observational | Recruiting | Non-Small Cell Lung Cancer, Minimal Residual Disease | 40 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921888) |
| November 6, 2026 | NCT07920822 | Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | Phase 1 | Enrolling by invitation | Soft Tissue Sarcoma, Non-small Cell Lung Cancer | 12 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920822) |
| November 5, 2026 | NCT07919691 | Proton Moderately Hypofractionated Radiotherapy in NSCLC Patients Unable to Tolerate Standard Concurrent Chemoradiotherapy | Ruijin Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 44 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919691) |
| November 5, 2026 | NCT07917767 | A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of... | Tang-Du Hospital | Phase 2 | Not yet recruiting | NSCLC Stage IIIA/B, NSCLC Stage II | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917767) |
| November 4, 2026 | NCT07916129 | Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for... | Tianjin Medical University Cancer Institute and Hospital | Not applicable | Enrolling by invitation | Non-Small Cell Carcinoma of Lung | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916129) |
| November 4, 2026 | NCT07914972 | Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC Patients | AstraZeneca | Observational | Not yet recruiting | Non-small Cell Lung Cancer, NSCLC, Stage I-II Unresected NSCLC | 440 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914972) |
| November 3, 2026 | NCT07912593 | Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors | Ensem Therapeutics | Phase 1/2 | Recruiting | Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer... | 320 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912593) |
| November 3, 2026 | NCT07912268 | Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 270 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912268) |
| November 2, 2026 | NCT07911449 | Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases | Cho Ray Hospital | Phase 2 | Recruiting | Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), EGFR Activating Mutation | 41 | Vietnam | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911449) |
| November 2, 2026 | NCT07911267 | Development and Utilization of an Integrated Clinical Genomic Database | Samsung Medical Center | Observational | Recruiting | Gastric Cancer, Colorectal Cancer, Lung Cancer (NSCLC), Liver Cancer, Pancreatic Cancer | 118,750 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911267) |
| November 2, 2026 | NCT07910942 | A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer | Kanvas Biosciences | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer | 40 | Canada, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910942) |
| November 2, 2026 | NCT07909343 | Patient Needs and Preferences for NSCL Cancer Treatment Monitoring | European Institute of Oncology | Observational | Recruiting | Lung Cancer (NSCLC) | 35 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909343) |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| November 2, 2026 | NCT07908745 | Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC | Ruijin Hospital | Phase 3 | Not yet recruiting | Non-Small-Cell Lung Cancer | 276 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908745) |
| November 2, 2026 | NCT07908732 | Risk-Adapted Segmental Esophagus-Sparing Radiotherapy for Definitive Non-Small Cell Lung Cancer | Ruijin Hospital | Phase 3 | Not yet recruiting | Non-Small Cell Lung Cancer | 140 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908732) |
| October 30, 2026 | NCT07906626 | Snakehead Fish Extract and Curcumin Co-Supplementation in Advanced Lung Cancer on Inflammation, Nutritional Status, and Quality of Life | Universitas Sumatera Utara | Not applicable | Completed | Lung Cancer (NSCLC) | 60 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906626) |
| October 30, 2026 | NCT07906158 | PET/CT-Based Intratumoral Heterogeneity and Multimodal Imaging for Tumor Diagnosis and Prognosis | Shengjing Hospital | Observational | Completed | Solid Neoplasms, Non-Small Cell Lung Cancer | 900 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906158) |
| October 29, 2026 | NCT07904013 | Impact of a Radiologic and Immunologic Signature on Cerebral Efficacy of Treatments in Lung Cancers With Brain Metastasis | University Hospital, Bordeaux | Observational | Not yet recruiting | Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Neoplasm Metastasis | 38 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904013) |
| October 29, 2026 | NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma... | 280 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903415) |
| October 29, 2026 | NCT07902921 | STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic... | National Cancer Institute (NCI) | Phase 1/2 | Not yet recruiting | NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer, Thymic Epithelial Tumors, TETs, Thymic Carcinomas... | 67 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902921) |
| October 28, 2026 | NCT07900581 | Analysis of Whole Exome and Transcriptome Sequencing to Identify Prognostic Biomarkers in Patients With Non-Small Cell Lung Cancer (NSCLC) | Hellenic Cooperative Oncology Group | Observational | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 300 | Cyprus, Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900581) |
| October 28, 2026 | NCT07899801 | A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC) | M.D. Anderson Cancer Center | Phase 1 | Not yet recruiting | Non Small Cell Lung Cancer | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899801) |
| October 27, 2026 | NCT07899086 | A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer | Hansoh BioMedical R&D Company | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer | 102 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899086) |
| October 27, 2026 | NCT07898241 | Using an Artificial Intelligence Software Tool (iSeg) During Radiation Treatment Planning for Patients With Lung Tumors | Northwestern University | Not applicable | Not yet recruiting | Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung | 34 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898241) |
| October 27, 2026 | NCT07897019 | Efficacy and Safety of Almonertinib Combined With Recombinant Human Endostatin in the Treatment of Stage IIIB-IV Non-small Cell Lung Cancer | Three Gorges Hospital of Chongqing University | Observational | Terminated | Non-Small Cell Lung Cancer | 1 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897019) |
| October 26, 2026 | NCT07896005 | A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Not yet recruiting | Non Small Cell Lung Cancer | 436 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896005) |
| October 26, 2026 | NCT07895238 | A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC | West China Hospital | Phase 3 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 1,088 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895238) |
| October 26, 2026 | NCT07894874 | A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. | InventisBio Yiqi Beijing Limited | Phase 1 | Not yet recruiting | Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer | 204 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894874) |
| October 26, 2026 | NCT07894367 | Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein... | Peking University Cancer Hospital & Institute | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 23 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894367) |
| October 23, 2026 | NCT07892300 | Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer | Oliver Jonas | Early phase 1 | Not yet recruiting | Lung Cancer, Mesothelioma, Suspected Lung Cancer, Suspected Mesothelioma | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892300) |
| October 22, 2026 | NCT07890714 | A Study of Dato-DXd in Participants With Solid Tumors \[TROPION-PanTumor04 (TP04)\] | Daiichi Sankyo | Phase 1/2 | Recruiting | Urothelial Cancer, Non-small Cell Lung Cancer | 268 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890714) |
| October 22, 2026 | NCT07890636 | Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC | Ruijin Hospital | Phase 2 | Not yet recruiting | Lung Neoplasm Malignant | 64 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890636) |
| October 22, 2026 | NCT07890493 | Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer | Canadian Cancer Trials Group | Phase 2 | Not yet recruiting | Non Small Cell Lung Cancer | 160 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890493) |
| October 22, 2026 | NCT07890246 | A Phase 1 Study of IM-1340 in Participants With Advanced Cancer | Immunome, Inc. | Phase 1 | Not yet recruiting | Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890246) |
| October 22, 2026 | NCT07890038 | The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant Tumors | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Observational | Active not recruiting | Nasopharyngeal Cancers, Lung Cancer (NSCLC), Esophageal Cancer, Glioma | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890038) |
| October 22, 2026 | NCT07889297 | Pulsed Field Ablation for the Treatment of Malignant Lung Tumors | Shanghai Chest Hospital | Not applicable | Not yet recruiting | Non-Small Cell Lung Cancer, Pulmonary Metastases | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889297) |
| October 22, 2026 | NCT07889232 | Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer | VA Office of Research and Development | Phase 1/2 | Not yet recruiting | Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss, Elevated Inflammatory Markers | 43 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889232) |
| October 22, 2026 | NCT07888075 | Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or... | AVEO Pharmaceuticals, Inc. | Phase 2/3 | Not yet recruiting | Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC), Metastatic Non-small Cell... | 950 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888075) |
| October 22, 2026 | NCT07887971 | A Study of \[225Ac\]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors | Aktis Oncology, Inc. | Phase 1 | Recruiting | NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage, B7H3, Prostate... | 152 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887971) |
| October 21, 2026 | NCT07886359 | Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy | Izmir Bakircay University | Not applicable | Not yet recruiting | Non-Small Cell Lung Cancer, Aerobic Exercise, Immunotherapy, Biomarker, Tumor Microenvironment, Handgrip Strength... | 78 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886359) |
| October 21, 2026 | NCT07886229 | Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer | Second Xiangya Hospital of Central South University | Phase 1 | Recruiting | Resectable Non-Small-Cell Lung Cancer | 9 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886229) |
| October 21, 2026 | NCT07885709 | MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC | Peking University People's Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer (NSCLC) | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885709) |
| October 20, 2026 | NCT07882940 | Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC | Sun Yat-sen University | Phase 2 | Not yet recruiting | Non-Small Cell Carcinoma of Lung, Locally Advanced | 24 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882940) |
| October 19, 2026 | NCT07880106 | Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Observational | Not yet recruiting | Lung Cancer Non-small Cell, Colorectal Cancer, Stomach Cancer, Hepatocellular Carcinoma, Breast Cancer | 2,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880106) |
| October 19, 2026 | NCT07879768 | Acupuncture and Laser Acupuncture for Advanced Non-Small Cell Lung Cancer | China Medical University, Taiwan | Not applicable | Not yet recruiting | Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung | 90 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879768) |
| October 16, 2026 | NCT07877584 | PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% | German Cancer Research Center | Phase 3 | Not yet recruiting | Non-Small Cell Lung Cancer | 406 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877584) |
| October 15, 2026 | NCT07875465 | Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases | Bing Xia | Phase 2 | Not yet recruiting | Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis), Pancreatic Cancer Metastatic, Solid Tumors | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875465) |
| October 15, 2026 | NCT07874984 | SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Not yet recruiting | Non Small Cell Lung Cancer | 220 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874984) |
| October 15, 2026 | NCT07874490 | Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC | NYU Langone Health | Phase 2 | Recruiting | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874490) |
| October 14, 2026 | NCT07874464 | Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally... | Sun Yat-sen University | Phase 2 | Not yet recruiting | Lung Cancer (NSCLC) | 256 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874464) |
| October 14, 2026 | NCT07873450 | SumMET: Study of \[225Ac\]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET | Full-Life Technologies UK Limited | Phase 1/2 | Recruiting | Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer, Cholangiocarcinoma | 208 | Australia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873450) |
| October 14, 2026 | NCT07873086 | MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC | Peking University People's Hospital | Not applicable | Not yet recruiting | Non-Small Cell Lung Cancer | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873086) |
| October 13, 2026 | NCT07871214 | A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage... | Bristol-Myers Squibb | Phase 2 | Not yet recruiting | Early-Stage Non-Small Cell Lung Cancer | 80 | Australia, Canada, China, France, Germany, Italy, Japan, Poland, Romania, South... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871214) |
| October 9, 2026 | NCT07869329 | Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer Patients | Duke University | Not applicable | Not yet recruiting | Non-Small Cell Lung Cancer, Radiation-Induced Cardiac Disease | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869329) |
| October 9, 2026 | NCT07869186 | Dermatological Effects and Quality of Life in Oncology Patients | European Institute of Oncology | Not applicable | Not yet recruiting | Breast Cancer, Ovarian Cancer, NSCLC (Non-small Cell Lung Cancer), Melanoma (Skin Cancer), Gynecological Cancer | 300 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869186) |
| October 8, 2026 | NCT07865910 | A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With... | Shanghai Henlius Biotech | Phase 2/3 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 1,438 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865910) |
| October 8, 2026 | NCT07864584 | Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced... | Nob Hill Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864584) |
| October 7, 2026 | NCT07863167 | An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer | 660 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863167) |
| October 7, 2026 | NCT07863024 | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET... | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 320 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863024) |
| October 5, 2026 | NCT07857694 | Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma | Laibin People's Hospital | Observational | Completed | Lung Cancer Stage III, EGFR Activating Mutation | 202 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857694) |
| October 5, 2026 | NCT07857616 | SI-B036-ST-101 in Advanced/Metastatic Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non... | 424 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857616) |
| October 2, 2026 | NCT07855965 | Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for... | West China Hospital | Phase 2 | Recruiting | Carcinoma, Non-Small-Cell Lung (NSCLC) | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855965) |
| October 2, 2026 | NCT07854769 | Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer | Fox Chase Cancer Center | Observational | Not yet recruiting | Non Small Cell Lung Cancer | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854769) |
| September 30, 2026 | NCT07849712 | An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or... | Zhejiang Cancer Hospital | Not applicable | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-small Cell... | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849712) |
| September 29, 2026 | NCT07848243 | Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes | Peking University Cancer Hospital & Institute | Phase 2 | Recruiting | Lung Cancer (NSCLC), Cervical Squamous Cell Cancer, Melanoma (Skin Cancer), Breast Cancer, Gastrointestinal Cancers | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848243) |
| September 29, 2026 | NCT07846358 | This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of... | Genfleet Therapeutics (Shanghai) Inc. | Phase 1/2 | Not yet recruiting | RAS Mutation, Non-small Cell Lung Cancer (NSCLC) | 84 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07846358) |
| September 29, 2026 | NCT07845916 | Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 12 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845916) |
| September 25, 2026 | NCT07842471 | Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC | Guangdong Provincial People's Hospital | Phase 2 | Not yet recruiting | NSCLC (Non-small Cell Lung Carcinoma) | 117 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842471) |
| September 25, 2026 | NCT07841249 | Cardiorespiratory Fitness After Lobectomy Versus Sublobar Resection | Tongji Hospital | Observational | Recruiting | Lung Cancer (NSCLC) | 604 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841249) |
| September 25, 2026 | NCT07841106 | Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases | Jiangmen Central Hospital | Phase 2 | Not yet recruiting | Lung Cancer (Non-Small Cell), Radiation, Brain Injury, Brain Edema, Brain Necrosis | 49 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841106) |
| September 24, 2026 | NCT07838532 | Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC | Xin Li | Observational | Completed | Non Small Cell Lung Cancer, T790M, EGFR Activating Mutation | 637 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838532) |
| September 23, 2026 | NCT07837739 | Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC | Tongji Hospital | Observational | Recruiting | Non-Small Cell Lung Cancer | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837739) |
| September 23, 2026 | NCT07836543 | Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer | Ming Chen | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 105 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836543) |
| September 22, 2026 | NCT07833085 | CAIX-targeted PET/CT in Solid Tumors | Zhongnan Hospital | Not applicable | Recruiting | Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma, Lung Cancer (NSCLC), Breast Cancer | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833085) |
| September 21, 2026 | NCT07829744 | Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Lung Cancer (NSCLC) | 190 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829744) |
| September 18, 2026 | NCT07828938 | Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality... | Fondation Hôpital Saint-Joseph | Not applicable | Not yet recruiting | Lung Cancer (Non-Small Cell) | 2,400 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828938) |
| September 18, 2026 | NCT07827885 | 20-Fr Versus 24-Fr Chest Drains After Uniportal VATS Lobectomy for NSCLC | Fondazione Policlinico Universitario Campus Bio-Medico | Not applicable | Completed | Non-Small Cell Lung Cancer | 80 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827885) |
| September 18, 2026 | NCT07827261 | A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer | 36 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827261) |
| September 17, 2026 | NCT07824882 | A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or... | Hansoh BioMedical R&D Company | Phase 2 | Recruiting | Non-Small Cell Lung Cancer | 76 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824882) |
| September 17, 2026 | NCT07824778 | Construction and Application Research of a Multidisciplinary Combined Exercise Management Program for Elderly Lung Cancer Patients After... | Sir Run Run Shaw Hospital | Not applicable | Completed | Lung Cancer (NSCLC) | 68 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824778) |
| September 16, 2026 | NCT07823855 | SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC | Second Affiliated Hospital, Zhejiang University, School of Medicine | Not applicable | Recruiting | Non-Small Cell Lung Cancer | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823855) |
| September 16, 2026 | NCT07823725 | TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling | Karolinska Institutet | Not applicable | Not yet recruiting | Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung) | 40 | Sweden | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823725) |
| September 16, 2026 | NCT07822984 | Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus... | Fudan University | Phase 2 | Not yet recruiting | EGFR-mutant Non-small Cell Lung Cancer, SBRT, NSCLC (Advanced Non-small Cell Lung Cancer) | 374 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822984) |
| September 16, 2026 | NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India | Eli Lilly and Company | Phase 4 | Not yet recruiting | Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung | 30 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822880) |
| September 16, 2026 | NCT07822542 | A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as... | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Carcinoma, Non-Small-Cell Lung | 448 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822542) |
| September 16, 2026 | NCT07821684 | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR... | AbbVie | Phase 3 | Not yet recruiting | Non-Squamous Non-Small Cell Lung Cancer | 660 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821684) |
| September 15, 2026 | NCT07819578 | Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC | Shaodong Hong | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819578) |
| September 14, 2026 | NCT07818304 | SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC | The First People's Hospital of Lianyungang | Phase 2 | Not yet recruiting | Non Small Cell Lung Cancer, Lung Neoplasms | 61 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818304) |
| September 14, 2026 | NCT07818135 | Comparison of Biportal Versus Multiportal Robotic Approaches for Pulmonary Resection in NSCLC | Carlos Déniz | Not applicable | Recruiting | Non-Small Cell Lung Cancer | 80 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818135) |
| September 14, 2026 | NCT07817329 | NUT Project: Nutritional Support in Thoracic Oncology | Casa di Cura Dott. Pederzoli | Observational | Recruiting | Oncologic Diseases, Lung Cancer (NSCLC) | 100 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817329) |
| September 11, 2026 | NCT07816380 | A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic... | Guangzhou JOYO Pharma Co., Ltd | Phase 3 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 216 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816380) |
| September 11, 2026 | NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers | European Institute of Oncology | Not applicable | Not yet recruiting | Non Small Cell Lung Cancer, Melanoma (Skin Cancer), Endometrial Cancer, Cervical Cancer | 360 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815873) |
| September 10, 2026 | NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a... | TwoStep Therapeutics, Inc. | Phase 1 | Recruiting | NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric... | 74 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814248) |
| September 9, 2026 | NCT07809763 | Wireless Wearable Home Prehabilitation for Older Adults With NSCLC | West China Hospital | Not applicable | Recruiting | Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery, Prehabilitation | 196 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809763) |
| September 9, 2026 | NCT07809256 | A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in... | EuroCityClinic LLC | Phase 3 | Recruiting | NSCLC (Non-small Cell Lung Cancer)R | 15 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809256) |
| September 8, 2026 | NCT07808138 | RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer | The Netherlands Cancer Institute | Phase 2 | Not yet recruiting | Non Small Cell Lung Cancer, Immunotherapy | 30 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808138) |
| September 8, 2026 | NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With... | AbbVie | Phase 1 | Recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer... | 130 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807956) |
| September 8, 2026 | NCT07807722 | Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC | Hubei Cancer Hospital | Phase 2 | Not yet recruiting | NSCLC (Non-small Cell Lung Cancer), EGFR, Neoadjuvant Therapy | 29 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807722) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| AstraZeneca | 18 | November 4, 2026 |
| Bristol-Myers Squibb | 18 | October 13, 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 17 | August 28, 2026 |
| Sun Yat-sen University | 16 | October 20, 2026 |
| Shanghai Pulmonary Hospital, Shanghai, China | 15 | August 10, 2026 |
| Fudan University | 14 | September 16, 2026 |
| Tianjin Medical University Cancer Institute and Hospital | 13 | November 4, 2026 |
| Pfizer | 12 | October 29, 2026 |
| West China Hospital | 12 | October 26, 2026 |
| Peking University Cancer Hospital & Institute | 11 | October 26, 2026 |
| Shanghai Chest Hospital | 11 | October 22, 2026 |
| Peking University People's Hospital | 9 | October 21, 2026 |
| The First Affiliated Hospital of Guangzhou Medical University | 9 | September 1, 2026 |
| Memorial Sloan Kettering Cancer Center | 8 | June 2, 2026 |
| Merck Sharp & Dohme LLC | 8 | April 28, 2026 |
| European Institute of Oncology | 7 | November 2, 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 7 | October 22, 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 7 | September 16, 2026 |
| Guangdong Association of Clinical Trials | 7 | July 10, 2026 |
| Tang-Du Hospital | 6 | November 5, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 275 | November 5, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 214 | November 9, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 143 | November 6, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 130 | November 6, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 101 | November 3, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 88 | November 2, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 17 | October 22, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 10 | October 23, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 9 | September 16, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 412 | November 6, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 260 | November 3, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 92 | October 13, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 88 | November 2, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 88 | October 29, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 75 | October 14, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 65 | November 6, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 57 | November 2, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 55 | November 9, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 53 | October 13, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 52 | October 22, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 52 | October 13, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 47 | July 31, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 42 | October 13, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 38 | July 31, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 31 | September 8, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 30 | October 28, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 30 | July 31, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 26 | July 31, 2026 |
| [Romania](https://specstream.ai/data/clinical-trials/country/romania) | 22 | October 13, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 22 | May 4, 2026 |
| [Austria](https://specstream.ai/data/clinical-trials/country/austria) | 21 | July 31, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 21 | April 7, 2026 |
| [Hungary](https://specstream.ai/data/clinical-trials/country/hungary) | 20 | August 3, 2026 |
| [Hong Kong](https://specstream.ai/data/clinical-trials/country/hong-kong) | 20 | August 3, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).